Compare BridgeBio Pharma Inc (BBIO) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? BridgeBio Pharma Inc trades at $84.7 (market cap $16.46B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.56. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | MSTZ | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $90.17 | $27.92 |
52-Week Low | $44.81 | $3.12 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
MSTZ trades at $13.16, up 5.07% today with a bullish technical signal from moving averages. The stock shows neutral oscillators but strong momentum indicators. Key support sits at $13 with resistance at $14. Recent ETF performance news highlights momentum strategies but lacks direct MSTZ coverage.
Outlook hinges on undisclosed fundamentals; current technical strength suggests near-term upside if $14 resistance breaks. Risks include absence of visible financial metrics and reliance on broader market trends. Investors need earnings clarity for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
